5 results about "Recurrent disease" patented technology

The invention relates to a tailorable anti-fungal multi-point penetrating press-fit sewing dressing and preparation and application thereof.The method comprises the following steps that a high polymer material solution and an anti-fungal medicine solution are mixed, liquid-phase matter is subjected to defoaming treatment, spinning is conducted, curing is conducted through a fixing solution, and the tailorable anti-fungal multi-point penetrating press-fit sewing dressing is obtained; performing rinsing, drying, opening, needling, freeze-drying and vacuum drying on the obtained condensate, and then compounding the condensate with a gelatin layer and a surface layer to obtain the tailorable antifungal multi-point penetrating press-fit sewing dressing. Compared with the prior art, the preparation method has the advantages that an antifungal drug is introduced and compounded with a high polymer material, the compound is prepared into the drug-containing fiber, and then the drug-containing fiber layer and other material layers are prepared into a final product through a modern textile technology. The product can realize long-acting sterilization and bacteriostasis, and solves the problems of difficult administration, poor curative effect, repeated disease course, patient compliance and the like of body surface fungal infection at present.

The present application provides the use of a nanocomposite with a core-shell structure. Specifically, the present application provides the use of a nanocomposite with a core-shell structure in the preparation of a drug for preventing and / or treating Clostridium difficile infection and recurrent diseases caused thereby, wherein the nanocomposite comprises: ZnO nanoparticles as a core; mesoporous silica as a shell coated on the surface of the ZnO nanoparticles; an antibiotic loaded in the pore channel of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite provided by the present application can achieve precise targeted release of the drug in the colon, and through the sequential and synergistic mechanism of "membrane breaking-sterilization-spore inhibition-repair", it can simultaneously solve multiple factors leading to CDI recurrence such as biofilm protection, spore storage, bacterial population destruction, mucosal damage, etc., and improve the treatment effect.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The present invention further relates to a composition comprising methanesulfonic acid and a non-aqueous proton acceptor for use in a method for the treatment and management of one or more of fistula, pilonidal sinus, herpes labialis, pyogenic granuloma, fungal nail infection and onicocriptosis.